Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults and Adolescents With Type 1 Diabetes

Type 1 Diabetes Clinical Trial

Official title:

An Open-label, Randomized, Three-way, Cross-over Study to Assess the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Conventional Pump Therapy in Regulating Glucose Levels During 24 Hours in Adults and Adolescents With Type 1 Diabetes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01754337
• Other study ID #: CLASS-03
• Status: Completed
• Phase: Phase 2
• First received: December 13, 2012
• Last updated: July 3, 2014
• Start date: December 2012
• Est. completion date: June 2014

Study information

• Verified date: July 2014
• Source: Institut de Recherches Cliniques de Montreal
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Ethics Review Committee
• Study type: Interventional

Clinical Trial Summary

Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormone: insulin and glucagon.

The main objective of this project is to compare the efficacy of single-hormone closed-loop strategy, dual-hormone closed-loop strategy and pump therapy to regulate glucose levels in a 24-hours in-patient study with standardized conditions in adults and adolescents with type 1 diabetes.

The investigators hypothesized that dual-hormone closed-loop strategy is more effective in regulating glucose levels in adults and adolescents with type 1 diabetes compared to single-hormone closed-loop strategy, which in turn is more effective than the conventional pump therapy.

Description:

Closed-loop strategy is composed of three components: glucose sensor to read glucose levels, insulin pump to infuse insulin and a dosing mathematical algorithm to decide on the required insulin dosages based on the sensor's readings. A dual-hormone closed-loop system would regulate glucose levels through the infusion of two hormone: insulin and glucagon.

We aim to conduct the 1st randomized three-way cross-over trial comparing single hormone closed-loop strategy, dual-hormone closed-loop strategy and the conventional pump therapy. We aim to compare the three interventions for 24 hours in adults and adolescents with type 1 diabetes. Each 24 hours will include a 60-min exercise session, three meals characterizing a full day, activities that mimick real-life conditions and an overnight stay. This study will also allow for multiple comparisons and evaluating the benefits of each component separately (i.e. the benefits of merely closing the loop with insulin alone vs. adding glucagon to the closed-loop strategy).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: June 2014
• Est. primary completion date: June 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

1. Males and females = 12 years of old.

2. Clinical diagnosis of type 1 diabetes for at least one year. The diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not needed.

3. The subject will have been on insulin pump therapy for at least 3 months.

4. HbA1c = 12%.

Exclusion Criteria:

1. Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator.

2. Recent (< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.

3. A recent injury to body or limb, muscular disorder, use of any medication or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the exercise protocol.

4. Pregnancy.

5. Severe hypoglycemic episode within two weeks of screening.

6. Current use of glucocorticoid medication (except low stable dose).

7. Known or suspected allergy to the trial products or meal contents.

8. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.

9. Anticipating a significant change in exercise regimen between admissions (i.e. starting or stopping an organized sport).

10. Failure to comply with team's recommendations (e.g. not willing to eat meals/snacks, not willing to change pump parameters, etc).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Type 1 Diabetes

Intervention

Other:
• Closed-loop system
Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning

Locations

Country	Name	City	State
Canada	Institut de recherches cliniques de Montréal	Montreal	Quebec

Sponsors (3)

Lead Sponsor	Collaborator
Institut de Recherches Cliniques de Montreal	McGill University, Montreal Children's Hospital of the MUHC

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of time of plasma glucose levels spent in target range.	Two-hour postprandial target range is between 4.0 and 10.0 mmol/l. Otherwise, target range is defined to be between 4.0 and 8.0 mmol/l.	24 hours	No
Secondary	Percentage of time of plasma glucose levels spent in the low range	Low range is defined to be a. below 4 mmol/L; b. below 3.5 mmol/L; c. below 3.3 mmol/L.	24 hours	No
Secondary	Percentage of overnight time of plasma glucose levels spent in the low range	Low range is defined to be a. < 4 mmol/L; b. < 3.5 mmol/L; c. < 3.3 mmol/L.	9 hours	No
Secondary	Standard deviation of glucose levels	Measure of glucose variability	24 hours	No
Secondary	Total insulin delivery		24 hours	No
Secondary	Mean plasma glucose level		24 hours	No
Secondary	Mean plasma glucose level		9 hours	No
Secondary	Mean plasma insulin concentration		24 hours	No
Secondary	Mean plasma glucagon concentration		24 hours	No
Secondary	Number of subjects experiencing hypoglycemia requiring oral treatment	Number of subjects experiencing hypoglycemia requiring oral treatment during a. the overall study period; b. the exercise; c. the night.	24 hours	No
Secondary	Percentage of time of plasma glucose levels spent between 4.0 and 10.0 mmol/L		24 hours	No
Secondary	Percentage of overnight time of plasma glucose levels spent between 4.0 and 8.0 mmol/L		9 hours	No
Secondary	Percentage of overnight time of plasma glucose levels spent between 4.0 and 10.0 mmol/L		9 hours	No
Secondary	Percentage of time of plasma glucose levels spent in the high range	High range is defined to be above a. 8.0 mmol/L; b. 10.0 mmol/L	24 hours	No
Secondary	Percentage of overnight time of plasma glucose levels spent in the high range	High range is defined to be above a. 8.0 mmol/L; b. 10.0 mmol/L.	9 hours	No